| CTA gene of interest |
% Tissue Expression(number of positive samples/total samples tested) |
Matched normal tissue tested? |
% Cell Line Expression
(number of positive samples/total samples tested) |
% Serological detection
(positive detection e.g. with ELISA/number of individuals tested) |
Comment |
| AKAP3 |
(5/6) 83.3% [109] |
No |
(3/10) 30% [109] |
|
|
| BCP-20(FBXO39) |
(22/57) 38.6% [66] |
No |
(2/7) 28.6% [32] |
|
Expressed weakly in normal ovary, placenta, lung and prostate |
| BCP-33 (LOC374973) |
(12/57) 21.1% [66] |
No |
|
|
Expressed weakly in normal pancreas |
| BCP-41(TTLL2) |
(17/57) 29.8% [66] |
No |
|
|
Weak expression in various normal tissues |
| BJ-HCC-20 |
(3/18) 16.7% [110] |
Yes |
|
|
|
| BORIS |
(8/10) 80% [111] |
No |
(3/4) 75% [33] |
|
|
| CAGE |
(35/47) 74.4% [55,64] |
Yes |
(2/4) 50% [112] |
(7/74) 9.9% [25,27] |
Expression seen in some normal colonic tissue (see main text for discussion) |
| CCDC62-2 |
(5/40) 12.5% [113] |
No |
|
(2/11) 18.2% [113] |
|
| CT16 |
(1/9) 11.1% [114] |
No |
|
|
CT16 has homology with GAGEfamily |
| CT45 |
(36/250) 14.4% [60] |
Yes |
|
|
|
| cTAGE-1 |
(6/39) 15.4% [100] |
No |
See comment |
|
Cell line and tissue expression frequency combined (31 tumours and 8 CRC cell lines used) |
| cTAGE-5A |
(13/39) 33.3% [100] |
No |
See comment |
|
See comment for cTAGE-1 |
| CTp11 |
(2/9) 22.2% [115] |
No |
|
|
|
| DBPC (CONTRIN) |
(9/10) 90% [116] |
No |
|
|
Protein production assessed using IHC – no PCR used |
| FATE(FATE-1, BCP-55) |
(3/14) 21.4% [117] |
Yes |
(0/2) 0% [23] |
|
|
| FAM46D |
(4*/18) 22.2% [118] |
No |
|
(0/18) 0% [118] |
*Number positive estimated from percentage displayed |
| GASZ |
(4*/18) 22.2% [118] |
No |
|
(0/18) 0% [118] |
*Number positive estimated from percentage displayed |
| HAGE |
(46/288) 16.0% [60,115,119] |
Yes, except [115] |
|
|
|
| IGSF11 |
(6/11) 54.5% [120] |
No |
|
|
|
| KP-CoT-23 (CCDC83) |
[122] |
|
|
(26/37) 70.3% [121] |
|
| LAGE-1 |
(68/503) 13.5% [55,60,61,122] |
Yes |
|
|
|
| LDHC |
(3/20) 15% [50] |
No |
|
|
|
| LEMD1 |
(17/18) 50.4% [123] |
Yes |
|
|
Used matched normal tissue but data not presented |
| MAGE-1 (MAGE-A1) |
(63/484) 13.0% [55,60,61,65,124] |
Yes, except [125] |
(7/12) 58.3% [58,65] |
(0/25) 0% [125] |
[58] – also tested CRC tissue but incomplete data provided |
| MAGE-2 (MAGE-A2) |
(62/338) 18.3% [55,60,65] |
Yes |
(6/17) 35.3% [58,65,85] |
|
[58] – also tested CRC tissue but incomplete data provided |
| MAGE-3 (MAGE-A3) |
(118/535) 22.1% [55,60,61,65,67,126] |
Yes, except [126] |
(7/24) 29.2% [65,127] |
(0/25) 0% [125] |
Note: MAGE-3 has extensive homology to MAGE-6 |
| MAGE-4 (MAGE-A4) |
(79/419) 18.9% [60,61,67] |
Yes |
(4/17) 23.5% [58,65,85] |
|
[58] – also tested CRC tissue but incomplete data provided |
| MAGE-A5 |
(17/250) 6.8% [60] |
Yes |
|
|
|
| MAGE-A6 |
(69/250) 27.6% [60] |
Yes |
(2/5) 40% [85] |
|
|
| MAGE-A10 |
(1/48) 2.1% [67] |
Yes |
|
|
|
| MAGE-A12 |
47%* or more [57] (0/34) 0% [55] |
Yes |
(4/4) 100% [58] |
|
*See main text for discussion. [58] – also tested CRC tissue but incomplete data provided |
| MAGE-C1 (CT7) |
(4/305) 1.3% [55,60,93,127] |
Yes, except [92] |
|
|
[128] – Identified by IHC in one sample but none by PCR |
| MAGE-C2 (CT10) |
(22/381) 5.8% [60,61,128] |
Yes, except [128] |
(1/2) 50% [50] |
|
CT10/MAGE-C2 shows extensive homology to CT7/MAGE-C1 |
| NXF2 |
(2/18) 11.1% [90] |
No |
|
|
|
| NY-ESO-1 |
(34/567) 6.0% [55,60,61,67,122,130] |
Yes, except [129] |
|
(1/107) 0.9% [61,125] |
|
| OY-TES-1 |
(2/13) 15.4% [130] |
No |
|
(6/58) 10.3% [130] |
|
| PAGE-4 |
(74/250) 29.6% [60] |
Yes |
|
|
|
| PASD1 |
(8*/18) 38.9% [118] |
No |
|
(0/18) 0% [118] |
*Number positive estimated from percentage displayed |
| POTE |
(7/7) 100% [68] |
No |
|
|
No normal colon tissue analysed in this study |
| SCP-1 |
(14/403) 3.5% [60,61,132] |
Yes, except [131] |
|
|
|
| SPAG9 |
(58/78) 74.3% [90] |
Yes |
(2/2) 100% [91] |
(38/54) 70.4% [91] |
Matched normal tissue obtained in 26 of 78 samples |
| SPANX |
(15/250) 6% [60] |
Yes |
|
|
|
| SSX-1 |
(10/561) 1.8% [55,60,61,122,132] |
Yes, except [131] |
|
|
|
| SSX-2 |
(37/641) 5.8% [55,60,61,67,122,132,132] |
Yes, except [132,133] |
|
(2/99) <2.0%*[73,125] |
*Unclear how many sera samples tested in [133] |
| SSX-4 |
(50/561) 8.9% [55,60,61,122,132] |
Yes, except [132] |
|
|
|
| SSX-5 |
(1/58) 1.7% [132] |
No |
|
|
|
| TEKT5 |
(5/10) 50% [134] |
No |
(4/44) 9.1% [134] |
|
|
| TPTE |
(13/264) 4.9% [60,117] |
Yes |
(0/2) 0% [117] |
|
|
| TRAG-3 |
(6/92) 6.5% [135,136] |
Yes but see comment |
(3/11) 27.3% [135] |
|
[136] – demonstrated weak expression in one adjacent normal tissue sample and also included two purchased cDNA CRCs not matched. |
| TSGA10 |
(1/20) 5% [137] |
No |
|
0% [137] |
|
| TSP50 |
(85*/95) 89.5% [92] |
No |
(7/7) 100% [92] |
|
*Assessed by IHC in CRC tissue. Weak positivity also in 60% of normal controls. |
| ZNF165 |
(6/14) 42.9% [138] |
Yes |
|
|
|
Abbreviations: IHC – Immunohistochemistry, PCR – Polymerase Chain Reaction, * – see comment on same row |
